Profiling of drugs for membrane activity using liposomes as an in vitro model system |
| |
Authors: | Grinius Leo Stanton David T Morris Charles M Howard Jeremy M Curnow Alan W |
| |
Affiliation: | a Procter & Gamble Pharmaceuticals, Mason, Ohio, U.S.A. |
| |
Abstract: | The increasing size of chemical libraries being analyzed by high-throughput screening results in a growing number of active compounds that need to be assessed before moving forward in the drug development process. As a consequence, more rapid and highly sensitive strategies are required to accelerate the process of drug discovery without increasing the cost. Due to the fact that significant numbers of compounds from combinatorial libraries are hydrophobic in nature, approaches are needed to evaluate the potential for these compounds to interfere with the functions of biological membranes. The liposome system was used to detect agents that act as follows: (i) ionophores able to induce specific ion permeability, e.g., valinomycin for K+ and protonophoric uncouplers for H+; (ii) ion antiporters which exchange H+ for other ions, e.g., nigericin; (iii) agents that form low specificity ion channels in the membrane, e.g., gramicidin; and (iv) detergents and other membrane-disrupting agents. We propose using this liposome assay during the drug development process to identify compounds that have membrane activity and, as a consequence, produce a biological effect by altering the physico-chemical properties of the cell membrane rather than interacting with a protein target. Screening of a representative set of biologically-active compounds (198) indicated that the majority of systemic antimicrobial drugs, but not topical drugs, lack membrane activity in this model system. |
| |
Keywords: | Drug testing Fluorescence Hydrophobicity Liposomes LogP Membrane activity Model membranes QSAR |
本文献已被 InformaWorld PubMed 等数据库收录! |
|